Q-linea Ab · OMXSTO:QLINEA
Q-linea Ab — Q4 2022 Earnings Presentation
17 slides from Q-linea Ab's earnings presentation, Feb 16, 2023
Slide 1: Future Proof Healthcare – Presentation Q4(22)
FUTURE PROOF HEALTHCARE A sustainable healthcare for a new generation Presentation Q4(22) Jonas Jarvius, CEO Anders Lundin, CFO/IR
Slide 2: Disclaimer
Disclaimer DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS
Slide 3: Q-linea 4th quarter
Headquarters, Marketing and demo lab, Consumable production in Uppsala Q-linea 4th quarter Q-linea is developing disruptive solutions for faster infectious disease diagnostics, first product targeting sepsis Q-linea AB founded a subsidiary in the US in December 2022. Q-linea is thus a group Introduc
Slide 4: Q-linea 4th quarter
Headquarters, Marketing and demo lab, Consumable production in Uppsala Q-linea 4th quarter Q-linea is developing disruptive solutions for faster infectious disease diagnostics, first product targeting sepsis Q-linea AB founded a subsidiary in the US in December 2022. Q-linea is thus a group Introduc
Slide 5: Rapid AST & a broad antimicrobial panel matters
Rapid AST & a broad antimicrobial panel matters: ASTar can provide up to 48 hours faster actionable results Transportation of blood culture from patient to laboratory: 1 – 24+ hours DAY 1 DAY 2 DAY 3 DAY 4 Plates are streaked CURRENT WORKFLOW Gram Susceptibility Patient to perform a Colony blood dra
Slide 6: Time to actionable results is important
Time to actionable results is important Sepsis is the most common cause of death in our hospitals More common than lung + prostate + breast-cancer combined Accounts for approximate 30% of all deaths in the hospital Most expensive condition to treat in the US. >27B USD1) Time to correct treatment is
Slide 7: An active quarter of customer visits
An active quarter of customer visits We have together with Thermo Fisher Scientific visited customers and sales leads During 2022, Thermo Fisher has performed several ASTar evaluations in Europe During fourth quarter, the Q-linea commercial team has visited and had meetings with all accounts Custome
Slide 8: Updated commercialisation strategy – first stage in 2023
Updated commercialisation strategy – first stage in 2023 Initially focus on key geographies in Europe and East coast in the USA & at the same time manage costs Goal is to demonstrate ASTar commercially & Enable a strong ramp-up in 2024 USA – Q-linea Inc. Most important market due to size and demonst
Slide 9: Customer evaluations of current rAST products
Customer evaluations of current rAST products A trend during 2022 was that customers asked for evaluations between the different rAST products on the market to guide future purchasing decisions Q-linea participates in a customer driven evaluation with a focus to evaluate three different rAST systems
Slide 10: ASTar performance is strong and it is easy to use
ASTar performance is strong and it is easy to use Evaluation of commercial systems for rapid antimicrobial susceptibility testing (rAST) of positive blood cultures: Comparison of susceptibility results View Sheffield Hospital’s scientific poster presentation from ECCMID 2022, featuring the ASTar Sys
Slide 11: Key highlights after period end
Key highlights after period end Q-linea initiates extended testing after feedback from the FDA The FDA's recommendation to conduct additional testing is prompted by an algorithm update and is primarily aimed at verifying the performance improvements brought about by the algorithm update. The update
Slide 12: Q-linea achieves full IVDR certification
Q-linea achieves full IVDR certification The new regulation for in-vitro diagnostic devices IVDR came into effect in May 2022 For a company to market in-vitro diagnostic devices in Europe they either had to be CE-marked and on the market before 26th May 2022, or the company holds IVDR certification.
Slide 13: Nexttobe offers extended loan facility
Nexttobe offers extended loan facility Having a strong owner that support the company and strategy is a key It has been a negative trend on Q-linea´s share price after the separation from Thermo Fisher Scientific. It is understandable that this cause stress among shareholders The board and managemen
Slide 14: Consolidated statement of profit and loss - fourth quarter
Consolidated statement of profit and loss - fourth quarter Net sales in the fourth quarter amounted to SEK 0 million (3.9). Operating result totalled SEK -59.6 million (-51.2). The company reported a loss after tax of SEK -63.7 million (-51.1). Earnings per share, before and after dilution amounted
Slide 15: Consolidated statement of financial position - end of year
Consolidated statement of financial position - end of year Cash and cash equivalents amounted to SEK 72.9 million (15.1) Total Short-term investments amounted SEK 0 million (150.9) which pertain of the current portion of non-current assets in 2021 (listed bonds). Non-current assets, listed bonds in
Slide 16: Cash flow statement fourth quarter
Cash flow statement fourth quarter Cash flow from operating activities SEK -79.7 million (-89.4). Decrease in cash outflow from operating activities mainly due to favourable changes in the working capital compared to the same quarter last year which is partly offset by lower Operating result. Cash f
Slide 17: Thank you
Looking forward to an exciting continuation of 2023 Q-linea wants to contribute to a healthier society by future- proofing a new generation of healthcare professionals, labs and hospitals. Thank you 17